



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/040,518	09/040,518 03/17/1998		COSTAS N. KARATZAS	06632/011001	1912	
20583	7590	04/13/2006	•	EXAMINER		
JONES DAY 222 EAST 41ST ST			`	FALK, ANN	FALK, ANNE MARIE	
NEW YORK, NY 10017				ART UNIT	PAPER NUMBER	
				1632		
				DATE MAILED: 04/13/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
09/040,518	KARATZAS ET AL.		
Examiner	Art Unit		
Anne-Marie Falk, Ph.D.	1632		

	Anne-wane Faik, Ph.D.	1032	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>06 March 2006</u> FAILS TO PLACE THIS AF	PLICATION IN CONDITION FOR	ALLOWANCE.	
1.   The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	n the same day as filing a Notice of wing replies: (1) an amendment, aff otice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mo	Appeal. To avoid aba idavit, or other eviden compliance with 37 Cl	ce, which R 41.31; or (3)
a) The period for reply expiresmonths from the mailing			
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I Examiner Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailing	g date of the final rejection	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropri inally set in the final Office	ate extension fee be action; or (2) as
2. ☑ The Notice of Appeal was filed on <u>06 March 2006</u> . A brie	of in compliance with 37 CFR 41.37	must be filed within to	vo months of
the date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any repl	or any extension thereof (37 CFR 4	11.37(e)), to avoid dis	missal of the
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief.	will not be entered be	ecause
(a) ☐ They raise new issues that would require further co			
(b) They raise the issue of new matter (see NOTE below		,,	
(c) They are not deemed to place the application in be appeal; and/or			he issues for
(d) They present additional claims without canceling a	corresponding number of finally rej	ected claims.	
NOTE: See Continuation Sheet. (See 37 CFR 1.1	• • •		
4. The amendments are not in compliance with 37 CFR 1.1	21. See attached Notice of Non-Co	mpliant Amendment (	PTOL-324).
5. Applicant's reply has overcome the following rejection(s)	);		•
<ol> <li>Newly proposed or amended claim(s) <u>39,40 and 60-63</u> v canceling the non-allowable claim(s).</li> </ol>	vould be allowable if submitted in a	separate, timely filed	amendment
7.  For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ll be entered and an e	xplanation of
Claim(s) objected to:			
Claim(s) rejected: <u>22-24,27-36,39-41 and 44-58</u> .			•
Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE	it hefere or on the date of filing a Ni	ntion of Annual will no	t he entered
<ol> <li>The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).</li> </ol>	d sufficient reasons why the affiday	it or other evidence is	necessary and
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar</li> </ol>	overcome all rejections under appea	al and/or appellant fai	ls to provide a
10. The affidavit or other evidence is entered. An explanation			
REQUEST FOR RECONSIDERATION/OTHER		•	
<ol> <li>The request for reconsideration has been considered bu See Continuation Sheet.</li> </ol>	it does NOT place the application in	n condition for allowar	ice because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	lo(s)	
13.			
	Anne-Marie Falk	∠Anne-Marie Falk, F	Ph.D.
	ANNE-MARIE FALK, PH.D PRIMARY FXAMINER	Primary Examiner Art Unit: 1632	

Application/Control Number: 09/040,518

Art Unit: 1632

Continuation Sheet (PTOL-303)

## Continuation of 3. NOTE:

If entered, the proposed amendment would require a new ground of rejection for newly added Claim 59. Claim 59 would be rejected under 35 U.S.C. 112, first paragraph, for lack of enablement. The newly added claim is directed, in relevant part, to a transgenic female ruminant comprising germline and somatic cells that comprise a nucleic acid molecule comprising a β-casein promoter operably linked to a nucleotide sequence (said nucleotide sequence further defined in the claim). The enablement rejection of record (see Office Action of 5/3/04 and that of 11/17/05) sets forth a scope of enablement that is limited to use of the mouse WAP promoter to drive expression of the nucleotide sequence recited in the claim. In the remarks submitted 3/6/06 (hereinafter referred to as "the response"), where Applicants assert that "new claim 41 [sic] ... recites a β-casein promoter" it is assumed that Applicants intended to refer to Claim 59. At page 6, paragraph 4 of the response, Applicants assert that this claim is fully enabled because transgenic ruminants expressing dragline silk polypeptides in milk under control of the β-casein promoter have been generated. Applicants point to the Declaration of Dr. Karatzas filed December 3, 2004 at paragraph 6. It is noted that paragraph 6 does not refer to the use of the β-casein promoter in those animals. On the contrary, paragraph 6 pertains only to goats comprising a transgene having the mouse WAP promoter. Although paragraph 4 states that transgenic female ruminants comprising a transgene having the β-casein promoter were generated, there is no information as to how they were generated and there is no evidence presented in the Declaration to suggest that dragline silk polypeptides expressed under the control of the β-casein promoter were expressed in quantities sufficient to permit their isolation from the milk. Thus, the rejection of record would apply to Claim 59, if entered.

Page 3

Application/Control Number: 09/040,518

Art Unit: 1632

Continuation Sheet (PTOL-303)

Continuation of 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:

As for the remainder of the response, Applicants' arguments, directed to the proposed claim amendments, are most because the proposed amendment has not been entered for the reasons noted above.

In view of the proposed amendments, if entered, the rejections of Claims 39 and 40 would be withdrawn and Claims 39, 40, and newly proposed Claims 60-63 would be allowable.

The rejections are maintained for reasons of record.